Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors.

ABSTRACT: Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to produce and deliver anticancer therapeutics that enhance cytotoxic T cell function and simultaneously inhibit immunosuppressive processes. Here, we review the potential of using T cells as therapeutic-secreting vehicles for immunotherapies and present theoretical and established arguments in support of further development of this unique cell-based immunotherapy.

SUBMITTER: Tsai AK 

PROVIDER: S-EPMC4910704 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature